Skip to main content
SpringerLink
Log in

Biomedical Aspects of Drug Targeting

  • Book
  • © 2002

Overview

Editors:
  1. Vladimir Muzykantov

    1. School of Medicine, University of Pennsylvania, Philadelphia, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Vladimir Torchilin

    1. School of Pharmacy, Northeastern University, Boston, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (25 chapters)

  1. Front Matter

    Pages i-xvii
    Download chapter PDF

  2. General Principles of Drug Targeting

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Strategies and Means for Drug Targeting: An Overview

      • Vladimir P. Torchilin
      Pages 3-26

    3. Biological Barriers for Drug Targeting

      • Vladimir R. Muzykantov
      Pages 27-44

  3. Cardiovascular Targeting

    1. Front Matter

      Pages 45-45
      Download chapter PDF

    2. Targeting the Pathological Myocardium

      • Ban-An Khaw
      Pages 47-67

    3. Targeting Atherosclerotic Plaques

      • Ban-An Khaw
      Pages 69-83

    4. Thrombus Targeting of Plasminogen Activators and Anticoagulants

      • Karlheinz Peter, Christoph Bode
      Pages 85-106

    5. Tissue-Specific Pharmacodelivery and Overcoming Key Cell Barriers in Vivo: Vascular Targeting of Caveolae

      • Lucy A. Carver, Jan E. Schnitzer
      Pages 107-128

    6. Targeting Pulmonary Endothelium

      • Vladimir R. Muzykantov
      Pages 129-148

    7. Targeting Inflammation

      • Jonathan R. Lindner, Alexander L. Klibanov, Klaus Ley
      Pages 149-172

    8. Intravascular Re-Targeting of Viral Vectors

      • Paul N. Reynolds, Sergei M. Danilov
      Pages 173-190

  4. Tumor Targeting

    1. Front Matter

      Pages 191-191
      Download chapter PDF

    2. Polymer-Drug Conjugates: Targeting Cancer

      • Ruth Duncan
      Pages 193-209

    3. Enhanced Permeability and Retention (EPR) Efect: Basis for Drug Targeting to Tumor

      • Hiroshi Maeda
      Pages 211-228

    4. Ligand-Directed Destruction of Tumor Vasculature

      • Sophia Ran, Michael Rosenblum, Philip E. Thorpe
      Pages 229-248

    5. Tumor Necrosis Treatment and Imaging of Solid Tumors

      • Alan L. Epstein, Leslie A. Khawli, Peisheng Hu
      Pages 249-274

    6. Targeted Apoptosis: Antibodies Linked to RNA Damaging Agents

      • Susanna M. Rybak, Michaela Arndt, Juergen Krauss, Dianne L. Newton, Bang K. Vu, Zhongyu Zhu
      Pages 275-290

    7. Immunotoxins and Antibody-Drug Conjugates for Cancer Treatment

      • Victor S. Goldmacher, Walter A. Blättler, John M. Lambert, Ravi V. J. Chari
      Pages 291-309

  5. Targeting to the Brain

    1. Front Matter

      Pages 311-311
      Download chapter PDF
Back to top

Keywords

About this book

Drugs usually have no natural affinity for the cells, tissues and organs where therapeutic effects are needed, which frequently results in low efficiency and unwanted side effects. This concern is even more profound when using highly potent and cytotoxic anticancer drugs or specific agents, such as enzymes and genetic materials, since their effective and safe action requires precise cellular or even sub-cellular addressing in the target organ. To meet safety, efficiency and specificity requirements, drugs somehow must be targeted to the sites of their expected therapeutic action. The idea of the "magic bullet," or drug targeting, proposed by Erlich a century ago, generates great and continuously growing interest in biomedical, industrial and financial circles. This book is focused on the strategies designed to target therapeutic or diagnostic agents to the disease sites. In an attempt to include in this volume the set of chapters reflecting both traditional and emerging areas of drug targeting, we have contacted many leading scientists in the field asking for their contributions. Their responses were most favorable and encouraging. As a result, we have succeeded in assembling a series of outstanding contributions reflecting practically all the key areas of drug targeting. The final structure of this book is as follows.

Editors and Affiliations

  • School of Medicine, University of Pennsylvania, Philadelphia, USA

    Vladimir Muzykantov

  • School of Pharmacy, Northeastern University, Boston, USA

    Vladimir Torchilin

Bibliographic Information

  • Book Title: Biomedical Aspects of Drug Targeting

  • Editors: Vladimir Muzykantov, Vladimir Torchilin

  • DOI: https://doi.org/10.1007/978-1-4757-4627-3

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 2002

  • Hardcover ISBN: 978-1-4020-7232-1Published: 28 February 2003

  • Softcover ISBN: 978-1-4419-5312-4Published: 06 December 2010

  • eBook ISBN: 978-1-4757-4627-3Published: 09 March 2013

  • Edition Number: 1

  • Number of Pages: XVII, 506

  • Topics: Biomedical Engineering and Bioengineering, Oncology, Polymer Sciences, Imaging / Radiology

Publish with us

Policies and ethics

Back to top

Search

Navigation